The Abuse Potential of Remoxy<sup>®</sup>, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone

Setnik, Beatrice; Roland, Carl L.; Cleveland, Jody M.; Webster, Lynn R.

doi:10.1111/j.1526-4637.2011.01093.x

Cited by 41 publications

(33 citation statements)

References 12 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bioavailability was reported in preclinical testing as consistent across multiple studies for a 40 mg dose [32]. An abuse potential study showed significantly lower drug likeability and thus potentially decreased abuse potential for both whole and crushed OC-R compared to both whole and crushed oxycodone immediate and extendedrelease preparations [35].…”

Section: Gelmentioning

confidence: 83%

Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

Schaeffer

2012

J. Med. Toxicol.

View full text Add to dashboard Cite

The increased use of opioid pain medication has been mirrored by the increased misuse and abuse of these drugs. As part of a multidisciplinary approach to this epidemic, pharmaceutical companies, with the encouragement of the Food and Drug Administration, have increased the development of abuse-deterrent formulations. While all have the goal of treating pain while mitigating misuse and abuse, there are different technologies utilized to impart the abuse-deterrent properties. The goal of this paper is to review the basis of abuse-deterrent formulations, the different types and approaches of some of the abuse-deterrent products, and their current regulatory status in the USA.

show abstract

Section: Gelmentioning

confidence: 83%

Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

Schaeffer

2012

J. Med. Toxicol.

View full text Add to dashboard Cite

show abstract

“…Setnik et al [55] compared the abuse potential of IR and ER oxycodone and the abuse potential of Remoxy Ò and found that crushed oxycodone IR and crushed oxycodone ER preparations in both fed and fasted states had significantly more abuse potential than Remoxy Ò when taken chewed or whole. The primary outcome was drug liking, using a 100 mm visual analog scale (VAS) score with 0 for no drug liking to 100 for extreme liking.…”

Section: Products Still In the Clinical Trialsmentioning

confidence: 99%

The Clinical Applications of Extended-Release Abuse-Deterrent Opioids

Vadivelu¹,

Schermer²,

Kodumudi³

et al. 2016

CNS Drugs

View full text Add to dashboard Cite

Opioids are the mainstay for treatment of acute pain and cancer pain, and also have a role in the treatment of chronic non-malignant pain. There has been, however, a growing public health problem stemming from the misuse of opioid analgesics leading to serious consequences. To deter abuse, new formulations of extended-release opioid analgesics and tamper-resistant opioids have recently been developed. The concept of abuse-deterrent extended-release opioids is relatively new and, although abuse may not be completely prevented, the utilization of such abuse-deterrent extended-release opioids could reduce this risk. Extended-release abuse-deterrent opioids have been found to have important clinical applications in cancer, acute pain, and chronic non-malignant pain for analgesia control with decreased incidence of tampering and abuse. In this review, different extended-release formulations of opioids available for clinical applications are presented with descriptions of the formulations, their physical properties, and the clinical studies performed to provide physicians with a better understanding of their uses.

show abstract

“…In addition, a lower maximum daily dose has been associated with a reduced risk of respiratory depression and overdose 32. The time to peak blood concentration level (T max ) is generally longer with ER formulations, a parameter that may confer a reduced abuse liability when intact tablets are taken whole (see below) 35,36. Two separate surveys, one sent to patients and the other to physicians, concluded that the two most important factors when selecting an opioid are the ability to relieve pain and the duration of pain relief 37.…”

Section: Managing Chronic Pain With Extended-release Opioidsmentioning

confidence: 99%

Update on prescription extended-release opioids and appropriate patient selection

Brennan¹

2013

JMDH

View full text Add to dashboard Cite

Chronic pain is largely underdiagnosed, often undertreated, and expected to increase as the American population ages. Many patients with chronic pain require long-term treatment with analgesic medications, and pain management may involve use of prescription opioids for patients whose pain is inadequately controlled through other therapies. Yet because of the potential for abuse and addiction, many clinicians hesitate to treat their patients with pain with potentially beneficial agents. Finding the right opioid for the right patient is the first – often complicated – step. Ensuring that patients continue to properly use the medication while achieving therapeutic analgesic effects is the long-term goal. Combined with careful patient selection and ongoing monitoring, new formulations using extended-release technologies incorporating tamper-resistant features may help combat the growing risk of abuse or misuse, which will hopefully reduce individual suffering and the societal burden of chronic pain. The objective of this manuscript is to provide an update on extended-release opioids and to provide clinicians with a greater understanding of which patients might benefit from these new opioid formulations and how to integrate the recommended monitoring for abuse potential into clinical practice.

show abstract

The Abuse Potential of Remoxy^®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone

Abstract: The abuse potential of Remoxy when taken whole or chewed was significantly lower than two comparators with known abuse potential, including oxycodone IR and crushed oxycodone ER, under the fed/fasted conditions tested. Remoxy may be associated with a reduced risk potential for abuse.

Cited by 41 publications

References 12 publications

Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

The Clinical Applications of Extended-Release Abuse-Deterrent Opioids

Update on prescription extended-release opioids and appropriate patient selection

Contact Info

Product

Resources

About

The Abuse Potential of Remoxy®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone

Abstract: The abuse potential of Remoxy when taken whole or chewed was significantly lower than two comparators with known abuse potential, including oxycodone IR and crushed oxycodone ER, under the fed/fasted conditions tested. Remoxy may be associated with a reduced risk potential for abuse.

Cited by 41 publications

References 12 publications

Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

The Clinical Applications of Extended-Release Abuse-Deterrent Opioids

Update on prescription extended-release opioids and appropriate patient selection

Contact Info

Product

Resources

About

The Abuse Potential of Remoxy^®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone